British Columbia Centre for Excellence In HIV/AIDS: Genetic Test
Predicts Response to Maraviroc in T
British Columbia Centre for Excellence In HIV/AIDS: Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients
(Thomson Reuters ONE) - VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 22, 2009) - A geneticapproach to determining HIV tropism can be used to effectivelyidentify patients who will respond to treatment with the CCR5antagonist maraviroc, according to new data presented today at the5th International AIDS Society (IAS) Conference on HIV Pathogenesis,Treatment and Prevention in Cape Town, South Africa.Using screening samples from patients enrolled in the maraviroctreatment-experienced clinical trial program, results of thisretrospective analysis showed that changes in HIV viral levels andthe percentage of patients who achieved undetectable viral loads werecomparable between those patients tested with HIV V3 Genotyping andTrofile(TM) (the recombinant-phenotypic assay originally used in theclinical trial program), indicating comparable accuracy of both testsat identifying treatment-experienced patients that will respond totreatment with maraviroc."HIV V3 Genotyping shows promise as a significantly faster and morecost-effective way to correctly identify patients who would benefitfrom CCR5 antagonists like maraviroc," said Richard Harrigan Ph.D.,lead investigator and Director of Research Laboratories, B.C. Centrefor Excellence in HIV/AIDS, Vancouver, Canada. "Since the genotypictest is based on methods that are already widely used through thesame labs that provide HIV drug resistance testing, this approachcould become broadly available and conducted at the same time asresistance testing to determine susceptibility to all drugs,including maraviroc."CCR5 antagonists, such as Pfizer's maraviroc, work by preventing HIVfrom entering CD4 cells via the CCR5 co-receptor. HIV V3 Genotypinguses HIV-tropism-prediction algorithms based on the genetic signatureof viruses that use this co-receptor.About the Analysis:The analysis was designed to compare the performance of genotypicassays versus the original Trofile in predicting virologic responseto maraviroc.Population-based sequencing was performed on screening samples frompatients enrolled in the maraviroc treatment-experienced clinicaltrials program, which included the MOTIVATE 1 and MOTIVATE 2(patients with R5 virus) and A4001029 (patients with non-R5 virus)studies. Results from MOTIVATE were used to support the approval ofmaraviroc in Canada, the U.S. and the EU for treatment-experiencedpatients with only CCR5-tropic HIV-1 detectable.HIV tropism was predicted using Geno2pheno (g2p), a widely availablealgorithm. Change in viral load at week eight was measured due to itbeing long enough to determine response to maraviroc and short enoughto be relatively unaffected by patient drop-outs and otherconfounding factors.Results show that at eight weeks a similar number of patients withCCR5 virus treated with maraviroc achieved undetectable virologicsuppression (less than 50 copies/mL or a greater than 2 log10copies/mL), regardless of which assay was used to identify theirtropism (g2p equals 71.9%, N equals 366; Trofile equals 71.6%, Nequals 380). A similar number of patients with CCR5 virus treatedwith maraviroc also achieved undetectable virologic suppression at 24weeks (less than 50 copies/mL), regardless of which assay was used toidentify their tropism (g2p equals 46.1%, N equals 393; Trofileequals 46.4%, N equals 405).Pfizer provided researchers of the study with samples and clinicaldata from the MOTIVATE 1 and 2, and A4001029 trials. Pfizer alsoassisted with the statistical analysis.About the B.C. Centre for Excellence in HIV/AIDS:The B.C. Centre for Excellence in HIV/AIDS is Canada's largestHIV/AIDS research, treatment and education facility. Located inVancouver, Canada, it is dedicated to improving the health of BritishColumbians with HIV through the development, monitoring anddissemination of comprehensive research and treatment programs forHIV and related diseases.Contacts:Karyo EdelmanIan Noble604.623.3007 ext. 300 or Mobile: 604.809.9650604.687.4304 (FAX)This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
" alt="Micrel Gives Industry Powerful Boost With Market's First High
Efficiency Low EMI Step-Up Regulator>">
" alt="Munters: Interim report January-June 2009>">
Datum: 22.07.2009 - 13:00 Uhr
Sprache: Deutsch
News-ID 3823
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"British Columbia Centre for Excellence In HIV/AIDS: Genetic Test
Predicts Response to Maraviroc in T"
steht unter der journalistisch-redaktionellen Verantwortung von
British Columbia Centre for Excellence in HIV/AIDS (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
